| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 07/13/2005 | CN1638792A FGFR agonists |
| 07/13/2005 | CN1638760A Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/13/2005 | CN1638753A Potentiation of therapeutic effects of fatty acids |
| 07/13/2005 | CN1638747A Sustained release pharmaceutical composition |
| 07/13/2005 | CN1638739A Compound for treating assuetude disturbance |
| 07/13/2005 | CN1638732A Sustained release drug formulations containing a carrier peptide |
| 07/13/2005 | CN1637416A Fp-ghrelin |
| 07/13/2005 | CN1637016A Non-aromatic estrogenic steroids with a hydrocarbon substituent in position 11 |
| 07/13/2005 | CN1637015A 17alpha-alkyl-17beta-oxy-estratrienes, uses thereof and pharmaceutical preparations |
| 07/13/2005 | CN1636994A Process of preparing alkali metal salys of hydrophobic sulfonamides and alkali metal salt produced thereby |
| 07/13/2005 | CN1636597A Compounds for the treatment of female sexual dysfunction |
| 07/13/2005 | CN1210400C Methods for making proteins contaniing free cysteine residues |
| 07/12/2005 | US6916834 Preparations and use of an Ah receptor ligand, 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester |
| 07/12/2005 | US6916832 Nitrogen compounds such as 8,9-dihydroxy-1,2,3,11b-tetrahydro-chromeno(4,3,2-de)isoquinoline hydrobromide, administered for prophylaxis of nervous system disorders |
| 07/12/2005 | US6916809 Heterocyclic acridone inhibitors of IMPDH enzyme |
| 07/12/2005 | US6916791 Androgen glycosides useful as contraceptives, for increasing muscle mass, and treatment of a hypogonadal disorder, androgen deficiency, sexual dysfunction and osteoporosis |
| 07/12/2005 | US6916788 Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof |
| 07/12/2005 | CA2298142C Soya extract, process for its preparation and pharmaceutical composition |
| 07/07/2005 | WO2004004779A8 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 07/07/2005 | US20050148636 Useful aroyl pyrrole heteroaryl methanones and methanols |
| 07/07/2005 | US20050148591 Tartrate salts of 5,8,14-triazatetracyclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen and pharmaceutical compositions thereof |
| 07/07/2005 | US20050148559 Fewer side effects; usable for longer period of time; lower recurrence rates after discontinuation; combination of progestogen and androgen components; kits |
| 07/07/2005 | US20050148497 Method for administering glp-1 molecules |
| 07/07/2005 | US20050147669 Rapid dissolution formulation of a calcium receptor-active compound |
| 07/07/2005 | US20050147583 Carbamylation to form a water soluble prodrug that has a biologically active agent linked to a water soluble non-immunogenic polymer; a hydrolyzing through carbamate bond; drug delivery; no enzymes or catalysts needed for release of acitve agent |
| 07/07/2005 | US20050147567 highly dispersible mixture of drugs and dipeptides or tripeptides, in the form of liquids, aerosols or powders, administered by inhalation |
| 07/07/2005 | DE202004002505U1 Oral hypoglycemic medicament, useful for treating type II diabetes mellitus, comprising cinnamon contained in a capsule which dissolves in the body, to avoid taste problems |
| 07/07/2005 | DE10356815A1 Use of an angiotensin II receptor antagonist for treating type 2 diabetes or prediabetes, for preventing diabetes or for treating metabolic syndrome and insulin resistance in patients with normal blood pressure |
| 07/06/2005 | EP1550720A1 Mutated androgen receptor, cancer cells expressing the same, method of constructing the same and use thereof |
| 07/06/2005 | EP1550454A1 Extracorporeal photopheresis in combination with anti-TNF treatment |
| 07/06/2005 | EP1549756A2 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 07/06/2005 | EP1549634A1 Novel substituted indoles |
| 07/06/2005 | EP1549632A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions |
| 07/06/2005 | EP1140145B1 Novel exendin agonist formulations and methods of administration thereof |
| 07/06/2005 | EP0730651B1 Surface loop structural analogues of fibroblast growth factors |
| 07/06/2005 | CN1636067A TACIs and BR3 polypeptides and uses thereof |
| 07/06/2005 | CN1636021A Preparation and use of solidified oils |
| 07/06/2005 | CN1636005A Benzothiazinone and benzoxazinone compounds |
| 07/06/2005 | CN1636003A Vitamin D3 derivatives and remedies using the same |
| 07/06/2005 | CN1635901A Remodeling and glycoconjugation of peptides |
| 07/06/2005 | CN1635898A Super-active porcine growth hormone releasing hormone analog |
| 07/06/2005 | CN1635878A Methods of treating cancer and the pain associated therewith with using endothelin antagonists |
| 07/06/2005 | CN1635832A Method for administering GLP-1 molecules |
| 07/06/2005 | CN1634355A Pure Chinese traditional medicine capsule for treating hyperthyroidism and simple goiter |
| 07/06/2005 | CN1634079A Compound estradiol valerate tablet and its preparation process |
| 07/06/2005 | CN1634001A Alkannin nano-granule and its preparation method |
| 07/06/2005 | CN1209353C Estrogen agonist/antagonist metabolites |
| 07/05/2005 | US6914074 For therapy and prophylaxis of prostatitis or interstitial cystitis, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis, prostatic hypertrophy, uterine leiomyomas, breast cancer, endometrial cancer |
| 07/05/2005 | US6914069 Pharmaceutically active compounds and methods of use |
| 06/30/2005 | WO2005058336A1 Production of hop extracts having oestrogenic and antiproliferative bioactivity |
| 06/30/2005 | WO2004065614A3 Suppression of cytotoxic protein conformers |
| 06/30/2005 | WO2004055009A8 Novel compounds having selective inhibiting efect at gsk3 |
| 06/30/2005 | WO2004055006A8 Novel compounds having selective inhibiting effect at gsk3 |
| 06/30/2005 | WO2004055005A8 Novel compounds having selective inhibiting effect at gsk3 |
| 06/30/2005 | WO2004002424A8 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 06/30/2005 | WO2003064629A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 06/30/2005 | US20050143464 With low side effects, which rapidly stimulate early insulin secretion and suppress blood glucose increase only at mealtimes; antidiabetic agent; triterpene acids or alcohols with picene ring; corosolic acids; oleanene acids; ursenoic acids; banaba plant extracts |
| 06/30/2005 | US20050143430 Catechol bioisosteres |
| 06/30/2005 | US20050143426 Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion |
| 06/30/2005 | US20050143408 Aporphine esters and their use in therapy |
| 06/30/2005 | US20050143364 21-Substituted progesterone derivatives as new antiprogestational agents |
| 06/30/2005 | US20050143360 dysmenorrhea; e.g. celecoxib and ethinyl estradiol and levonorgestrel; side effect reduction as lower doses possible |
| 06/30/2005 | US20050142617 gene related to bone density; possible use in the drug screening, treatment, and diagnosis of bone disorders such as osteoporosis |
| 06/30/2005 | US20050142173 Testosterone hydroalcoholic gel for transdermal use; unique pharmacokinetic steady-state profile for testosterone |
| 06/30/2005 | US20050142155 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 06/30/2005 | US20050142072 Drug delivery into nose; controlling concentration into blood; using opioid or non-steroil antiinflammatory dryg |
| 06/30/2005 | CA2550695A1 Glp-1 pharmaceutical compositions |
| 06/30/2005 | CA2549662A1 A method for the production of enriched hop extracts having combined oestrogenic and antiproliferative bioactivity |
| 06/30/2005 | CA2549603A1 1-n-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them |
| 06/29/2005 | EP1548024A1 Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| 06/29/2005 | EP1547614A1 Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof |
| 06/29/2005 | EP1547579A1 Adhesive gel composition for iontophoresis preparation and process for producing the same |
| 06/29/2005 | EP1546235A2 Water-soluble polymer alkanals |
| 06/29/2005 | EP1545621A1 Carrier |
| 06/29/2005 | EP1545572A2 Conjugates activated by cell surface proteases and therapeutic uses thereof |
| 06/29/2005 | EP1545560A2 Inhibition of protein kinase c alpha for treatment of diabetes mellitus and cardiovascular diseases |
| 06/29/2005 | EP1545547A1 17&bgr;-ESTRADIOL/LEVONORGESTREL TRANSDERM PATCH FOR HORMONE REPLACEMENT THERAPY |
| 06/29/2005 | EP1274701B1 [1,4']-bipiperidine compounds |
| 06/29/2005 | CN1633498A Novel insulin/IGF/relaxin family polypeptides and dnas thereof |
| 06/29/2005 | CN1633433A N-aroyl cyclic amines |
| 06/29/2005 | CN1633421A Oxazole/thiazol-derivatives activators of the hppar-alpha receptor |
| 06/29/2005 | CN1633420A Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors |
| 06/29/2005 | CN1633414A Chemical compounds |
| 06/29/2005 | CN1633301A Extracts from sophora, production method and purposes thereof |
| 06/29/2005 | CN1633299A Estrogen replacement therapy |
| 06/29/2005 | CN1633296A Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 06/29/2005 | CN1633294A 2, 4, 5-trisubstituded thiazolyl derivatives and their antiinflammatory activity |
| 06/29/2005 | CN1633287A Biphenil derivatives and their use as antiandrogenic agents |
| 06/29/2005 | CN1633284A Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
| 06/29/2005 | CN1633282A Orodispersible effervescent tablets |
| 06/29/2005 | CN1208066C Use of cyclic ether for preparation of medicaments affecting glucose tolerance |
| 06/29/2005 | CN1208055C Use of amino acids for making medicine for treating to insulin-resistance |
| 06/28/2005 | US6911459 Pharmaceutical composition |
| 06/28/2005 | US6911447 Non-aromatic carbocyclic rings; aromatic carbocyclic rings; non-aromatic heterocyclic rings; aromatic heterocyclic rings; compositions comprising the ligands of the invention as well as methods of treating diseases mediated through MC-3/MC-4 |
| 06/28/2005 | US6911426 Inhibitor of apoptosis proteins (IAP); survivin |
| 06/23/2005 | US20050136041 Transgenic cell comprising nucleotide sequences coding erythropoietin and/or glucagon-like peptides for use in treatment and prevention of blood and metabolic disorders; somatic and germ cell gene therapy; tissue engineering |
| 06/23/2005 | US20050136032 Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| 06/23/2005 | CA2490218A1 Extracorporeal photopheresis in combination with anti-tnf treatment |
| 06/22/2005 | EP1543834A1 Production of hop extracts having oestrogenic and antiproliferative bioactivity |
| 06/22/2005 | EP1543722A1 Nonhuman animal reproducing pathogenic conditions of spinal and bulbar muscular atrophy and remedy for spinal and bulbar muscular atrophy |